232 related articles for article (PubMed ID: 35764914)
1. Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China.
Zhang Y; Wei Y; Li H; Chen Y; Guo Y; Han S; Shi L; Guan X
Pharmacoeconomics; 2022 Jul; 40(7):715-724. PubMed ID: 35764914
[TBL] [Abstract][Full Text] [Related]
2. Price negotiation and pricing of anticancer drugs in China: An observational study.
Zhou J; Lan T; Lu H; Pan J
PLoS Med; 2024 Jan; 21(1):e1004332. PubMed ID: 38166148
[TBL] [Abstract][Full Text] [Related]
3. Promoting Access to Innovative Anticancer Medicines: A Review of Drug Price and National Reimbursement Negotiation in China.
Mingge X; Jingyu W; Qi L; Zhe Z; Qing R
Inquiry; 2023; 60():469580231170729. PubMed ID: 37171066
[TBL] [Abstract][Full Text] [Related]
4. Health technology assessment-informed pricing negotiation in China: higher negotiated price for more effective targeted anticancer medicines?
Huang C; Ung COL; Wushouer H; Bai L; Huang T; Li X; Guan X; Shi L
Health Res Policy Syst; 2022 Jan; 20(1):3. PubMed ID: 34980159
[TBL] [Abstract][Full Text] [Related]
5. Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy.
Trotta F; Mayer F; Barone-Adesi F; Esposito I; Punreddy R; Da Cas R; Traversa G; Perrone F; Martini N; Gyawali B; Addis A
BMJ Open; 2019 Dec; 9(12):e033728. PubMed ID: 31826897
[TBL] [Abstract][Full Text] [Related]
6. The correlation between the costs and clinical benefits of national price-negotiated anticancer drugs for specific cancers in China.
Bao Y; Liu Y; Ma R; Zhang P; Li X
J Glob Health; 2023 Nov; 13():04140. PubMed ID: 37934965
[TBL] [Abstract][Full Text] [Related]
7. The impact of government reimbursement negotiation on targeted anticancer medicines use and cost in China: A cohort study based on national health insurance data.
Yang Y; Zhang Y; Wagner AK; Li H; Shi L; Guan X
J Glob Health; 2023 Aug; 13():04083. PubMed ID: 37566690
[TBL] [Abstract][Full Text] [Related]
8. The usage and costs of national drug price-negotiated anticancer medicines in a first-tier city in Northeast China: a study based on health insurance data.
Li BX; Wang YQ; Yi YY; Zhou N; Lv ZX; Ma R; Li X; Yuan N
BMC Public Health; 2024 May; 24(1):1309. PubMed ID: 38745323
[TBL] [Abstract][Full Text] [Related]
9. Trends of Negotiated Targeted Anticancer Medicines Use in China: An Interrupted Time Series Analysis.
Huang C; Ung COL; Wushouer H; Bai L; Li X; Guan X; Shi L
Int J Health Policy Manag; 2022 Aug; 11(8):1489-1495. PubMed ID: 34273922
[TBL] [Abstract][Full Text] [Related]
10. Progress on drug pricing negotiations in China.
Tang M; Song P; He J
Biosci Trends; 2020 Jan; 13(6):464-468. PubMed ID: 31875587
[TBL] [Abstract][Full Text] [Related]
11. The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China.
Zhang Y; Wushouer H; Han S; Fu M; Guan X; Shi L; Wagner A
BMJ Glob Health; 2021 Jul; 6(7):. PubMed ID: 34266848
[TBL] [Abstract][Full Text] [Related]
12. Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: A controlled interrupted time series study.
Cai L; Tao T; Li H; Zhang Z; Zhang L; Li X
J Glob Health; 2022 Dec; 12():11016. PubMed ID: 36527382
[TBL] [Abstract][Full Text] [Related]
13. Can locally developed me-too drugs aid price negotiation? An example of cancer therapies from China.
Luo Z; Gyawali B; Han S; Shi L; Guan X; Wagner AK
Semin Oncol; 2021 Apr; 48(2):141-144. PubMed ID: 33875231
[TBL] [Abstract][Full Text] [Related]
14. Recent Pricing Negotiations on Innovative Medicines Pilot in China: Experiences, Implications, and Suggestions.
Li H; Liu GG; Wu J; Wu JH; Dong CH; Hu SL
Value Health Reg Issues; 2018 May; 15():133-137. PubMed ID: 29705645
[TBL] [Abstract][Full Text] [Related]
15. The price, efficacy, and safety of within-class targeted anticancer medicines between domestic and imported drugs in China: a comparative analysis.
Luo X; Du X; Huang L; Guo Q; Tan R; Zhou Y; Li Z; Xue X; Li T; Le K; Qian F; Chow SC; Yang Y
Lancet Reg Health West Pac; 2023 Mar; 32():100670. PubMed ID: 36785854
[TBL] [Abstract][Full Text] [Related]
16. Lessons From The Impact Of Price Regulation On The Pricing Of Anticancer Drugs In Germany.
Lauenroth VD; Kesselheim AS; Sarpatwari A; Stern AD
Health Aff (Millwood); 2020 Jul; 39(7):1185-1193. PubMed ID: 32634355
[TBL] [Abstract][Full Text] [Related]
17. Access to innovative anticancer medicines in China: a national survey on availability, price and affordability.
Li W; Lu W; Chen H; Zhang C; Wang M; Zheng F; Wu HH; Wan GW; Yang Q; Ye L
BMJ Open; 2024 Apr; 14(4):e077089. PubMed ID: 38670605
[TBL] [Abstract][Full Text] [Related]
18. The Impact of Price Negotiations on Public Procurement Prices and Access to 8 Innovative Cancer Medicines in a Middle-Income Country: The Case of Mexico.
Moye-Holz D; van Dijk JP; Reijneveld SA; Hogerzeil HV
Value Health Reg Issues; 2019 Dec; 20():129-135. PubMed ID: 31374426
[TBL] [Abstract][Full Text] [Related]
19. Differences in reimbursement listing of anticancer therapies in China: an observational study.
Guan X; Zhang Y; Wushouer H; Shi L; Ross-Degnan D; Wagner AK
BMJ Open; 2020 Jan; 10(1):e031203. PubMed ID: 31911513
[TBL] [Abstract][Full Text] [Related]
20. Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe.
Vokinger KN; Hwang TJ; Daniore P; Lee CC; Tibau A; Grischott T; Rosemann TJ; Kesselheim AS
JAMA Oncol; 2021 Sep; 7(9):e212026. PubMed ID: 34196656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]